Nitorum Capital buys $10,690,923 stake in Haemonetics Corporation (HAE)

Haemonetics Corporation (HAE) : Nitorum Capital scooped up 112,312 additional shares in Haemonetics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 294,922 shares of Haemonetics Corporation which is valued at $10,690,923.Haemonetics Corporation makes up approximately 4.77% of Nitorum Capital’s portfolio.

Other Hedge Funds, Including , Hightower Advisors sold out all of its stake in HAE during the most recent quarter. The investment firm sold 8,528 shares of HAE which is valued $309,140.Cambiar Investors reduced its stake in HAE by selling 952,363 shares or 97.44% in the most recent quarter. The Hedge Fund company now holds 25,030 shares of HAE which is valued at $752,152. Haemonetics Corporation makes up approx 0.01% of Cambiar Investors’s portfolio. Kirr Marbach Co In added HAE to its portfolio by purchasing 7,260 company shares during the most recent quarter which is valued at $218,163. Haemonetics Corporation makes up approx 0.04% of Kirr Marbach Co In’s portfolio.Gemmer Asset Management boosted its stake in HAE in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 105 shares of Haemonetics Corporation which is valued at $3,105.

Haemonetics Corporation opened for trading at $37.18 and hit $37.53 on the upside on Thursday, eventually ending the session at $37.32, with a gain of 0.43% or 0.16 points. The heightened volatility saw the trading volume jump to 3,00,212 shares. Company has a market cap of $1,914 M.

On the company’s financial health, Haemonetics Corporation reported $0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 1, 2016. Analyst had a consensus of $0.29. The company had revenue of $210.00 million for the quarter, compared to analysts expectations of $205.41 million. The company’s revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.35 EPS.

Many Wall Street Analysts have commented on Haemonetics Corporation. Haemonetics Corporation was Downgraded by Sidoti to ” Neutral” on Aug 15, 2016. Company shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $32 .Company shares were Reiterated by The Benchmark Company on Aug 2, 2016 to “Hold”, Firm has raised the Price Target to $ 32 from a previous price target of $28 .

Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *